# Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria

> **NCT00149383** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mahidol University** · enrollment: 140 (actual)

## Conditions studied

- Falciparum Malaria

## Interventions

- **DRUG:** Rosiglitazone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00149383
- **Lead sponsor:** Mahidol University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2005-11
- **Final completion:** 2006-01
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2015-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00149383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00149383, "Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT00149383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*